ArticleBlood cancer journal2023

BCMA-targeted bortezomib nanotherapy improves therapeutic efficacy, overcomes resistance, and modulates the immune microenvironment in multiple myeloma.

Debasmita Dutta et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.